Language selection

Government of Canada / Gouvernement du Canada

Search

Drug Establishment Licence application form (FRM-0033)

PDF Version

Application Information

Table 1. Drug establishment licence information (existing DEL holders only)

Drug Establishment Licence (DEL) # (if applicable):

Table 2. Application type

Table 3. Summary of amendment type(s)

Add or Remove or Modify

Part A: Company information:

Part B: Canadian building information:

Section 1
Building name:
Address information:
Contact information:

Section 3.0/3.1
Activity:
Category:
Drug Class:
Class:

Section 4.0/4.1
Product information:
Foreign building information:

Section 5.0/5.1
Company name:
Building name:
Address information:
Activity:
Category:
Class:
Product information:

Part C: Canadian warehouse:
Part D: Alternate sample retention site:

Table 4. Fee information and attachments

Small business mitigation:

Option 1 (both boxes must be selected):

We certify that we meet the definition of a small business at the time of this filing and have applied for small business status for our company with Health Canada and have received confirmation prior to submitting this submission/application.

We understand that failure to hold a valid small business status with Health Canada at the time of submitting this submission/application will result in the full fee being charged.

Option 2:

I am not applying for the small business mitigation.

Important: If left blank, or if option 2 is selected, the full fee will be charged and you will not be considered for the small business mitigation.

Fee exemption

I certify that I meet the definition of a Publicly Funded Health Care Institution.

I certify that I am a branch or agency of the Government of Canada or of a province or territory.

See section 3 of the Fees in Respect of Drugs and Medical Devices Order for more details at https://laws-lois.justice.gc.ca/eng/regulations/SOR-2019-124/FullText.html.

DEL calculation chart

I have attached the completed DEL calculation chart.

Table 5. Other attachments

Part A: Company information
Company name:
DEL # (if applicable):
Is this establishment a DIN owner? Yes or No
Drug class: Human or Human and veterinary or Veterinary only

Company address
Building name or number (if applicable):
Street:
Suite and/or P.O. box:
City:
Province:
Postal code:
Contact person and title:
Language: English or French
Telephone:
Fax:
Email:

Mailing address: or same as establishment address
Company name (if different from establishment name):
Street:
Suite and/or P.O. box:
City:
Province:
Postal code:
Mailing contact and title:
Language: English or French
Telephone:
Fax:
Email:

Billing address: or same as establishment address or same as mailing address
Company name (if different from establishment name):
Street:
Suite and/or P.O. box:
City:
Province:
Postal code:
Billing contact and title:
Language: English or French
Telephone:
Fax:
Email:

Emergency contact information (24/7 or outside business hours)
Contact person and title:
Language: English or French
Telephone:
Fax:
Email:

Signature of signing authority
Name of authorized signing official:
Title:
Signature:
Date (yyyy-mm-dd):

Part B: Canadian building information

Section 1.0: Address information: same as establishment address or same as mailing address or same as billing address

Building name or number (if applicable):
Dwelling-house: Yes or No
DEL # (if applicable):
Street:
Suite or P.O. box:
City:
Province:
Postal code:
Contact Person:
Language: English or French
Title:
Email:
Phone:
Fax:

Section 2: Drug Good Manufacturing Practices (GMP) inspection information

Has this building undergone a drug GMP inspection by a Health Canada inspector: Yes or No

Date of last drug GMP inspection (yyyy-mm-dd):

Section 3.0: Domestic finished dosage form class information

Activity:

Category:

Enter only one category per line

  1. Came into force December 19, 2013 (Repeal of Schedule F)
  2. Came into force October 17th, 2018

Class of finished dosage forms:

Please use the dosage form associated with the drug's market authorisation issued by Health Canada available in the Drug Product Database online query
at https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Enter all that apply.
(S) is used to indicate sterile dosage
e.g. 1, 2, 3 1 Solution-S, powder-S, tablet, capsule

Section 3.1: Domestic active pharmaceutical ingredient information

Activity:

Category:

Drug Class:

Class of final API forms:

  1. Active pharmaceutical ingredients set out in List A that are for veterinary use.
  2. The sterilization of API should be entered in section 3 under the activity fabricate and the drug category Pharmaceutical, dosage form API (solid, liquid or gas).

e.g. 4 1, 2 Yes No 1, 2

Section 4.0: Domestic Finished Dosage Form (FDF) class product information

Product name:
Drug class: H1 V2
Schedule / PDL3:
DIN4:
Activity 5: F P/L T6 D6 W6

  1. Drug for human use
  2. Drug for veterinary use
  3. Drug category listed in Table 2 of section C.01A.008 of the Food and Drug Regulations
  4. Drug Identification Number
  5. F=Fabricate, P/L=Package/Label, T=Test, D=Distribute, W=Wholesale
  6. For the activity of test, distribute and wholesale, it is only required to provide drug information for drugs that are narcotics as defined in the Narcotic Control Regulations or controlled drugs as defined in subsection G.01.001(1) in the Food and Drug Regulations

Section 4.1: Domestic Active Pharmaceutical Ingredients (API) information (complete only if applying to fabricate and package/label)

API name:
Associated Drug Identification Number (DIN):
Activity: F P/L

Section 5.0: Finished Dosage Form (FDF) foreign building information

Foreign company name and building address information

Foreign company name:
Foreign building name:
Street:
City:
Province/State:
Country:
Postal code/ZIP code:
Building in an MRA country? Yes or No
Are activities covered by an MRA? Yes or No
Reason for submission: Renew(NERBY) Add Remove Amend

Canadian building information (complete only if submitting Section 5 separately)

Canadian company name:
Drug establishment licence number (10XXXX-X/3-00XXXX-X):
Contact person and title:
Telephone:
Fax:
Email:
Name of authorized signing official:
Title:
Signature:
Date (yyyy-mm-dd):

Activity, Category and Dosage Form Class Information

Activity:

Category:
Enter only one category per line.

  1. Came into force December 19, 2013 (Repeal of Schedule F)
  2. Came into force October 17th, 2018

Class of finished dosage form:
Please use the finished dosage form associated with the drug's market authorisation issued by Health Canada available in the Drug Product Database online query at https://health-products.canada.ca/dpd-bdpp/index-eng.jsp.

Enter all that apply. (S) is used to indicate sterile dosage form.

e.g. 1, 3a,3b,3h 1 Solution-S, powder-S, tablet, capsule

Finished Dosage Form (FDF) Product Information (Complete only if applying for: fabricate, package/label and/or test)

Product name:
Drug class: Human Vet.
Schedule / PDL1:
DIN2:
Activity: F3 P/L3 T3

  1. Drug category listed in Table 2 of section C.01A.008 of the Food and Drug Regulations
  2. Drug Identification Number
  3. F=Fabricate, P/L=Package/Label, T=Test

Required GMP evidence documents

The final and most recent (within the last 3 years) inspection report signed issued by:

The corrective actions taken, signed by a responsible official of the foreign building (if applicable): Yes or No.
A copy of the Site Master File, or a similar document such as a quality manual: Yes or No.
A Letter of Authorization (LoA) to reference a GMP evidence package from a previously submitted application: Yes or No.

Section 5.1: Active pharmaceutical ingredients foreign building information
Canadian building information (complete only if submitting Section 5.1 separately)

Canadian company name:
Drug establishment licence number (10XXXX-X/3-00XXXX-X):
Contact person and title:
Phone:
Fax:
Email:

Attestation and undertaking
I <name> attest to the following statements:

  1. I have signing authority for <DEL applicant/company name> and am the contact person with respect to this application and any subsequent related matters that may arise.
  2. All the information about the foreign buildings presented in this application is up to date, accurate and complete.
  3. The records regarding the quality of the active pharmaceutical ingredient in support of Table A are maintained on my premises at <address>.

I understand that Health Canada may at any time request and/or inspect the records relevant to determining the foreign building's compliance with the applicable Good Manufacturing Practices (GMP) requirements, notwithstanding the fact that I am not required to provide them to Health Canada at this time as part of this application. I undertake to provide any requested records in one of the two official languages of Canada (English or French) within 48 hours of receiving the request from Health Canada in writing. In the event that a situation arises where the health and safety of Canadians is potentially at risk, I undertake to make every reasonable effort to provide them to Health Canada on an expedited basis.

I further undertake to notify Health Canada if an event occurs at any foreign building that could affect the quality, safety or efficacy of an active pharmaceutical ingredient.

Name of senior official:
Title of senior official:
Signature of senior official:
Date (yyyy-mm-dd):
Name of quality assurance official:
Title of quality assurance official:
Signature of quality assurance official:
Date (yyyy-mm-dd):

Foreign buildings conducting API-related licensable activities

A Table A must be submitted with your FRM-0033.

Note: (1) If Table A is not completed, the application will be treated as incomplete. Submit Table A along with FRM-0033 electronically.

(2) Applications that do not include the most recent version of Table A (available from DELU at hc.del.questions-leppp.sc@canada.ca) will be treated as incomplete.

SECTION 5.2 Active pharmaceutical ingredients - non-compliant foreign building information

Foreign building name and address information

Foreign company name:
Street:
City:
Province/State:
Country:
Postal code/ZIP code:

Activity, category and dosage form class information

Activity:

Category:

Class of Final API Form:

e.g. 1, 2 1 1, 2

Part C: Canadian Warehouse Information

Warehouse company name:
Building name (if applicable):
Date of last drug GMP inspection (yyyy-mm-dd):
This warehouse is used for storage of products from DEL # (10XXXX-X/3-00XXXX-X):
Street Address:
Suite and/or P.O. box:
City:
Province:
Postal code:
Contact person and title:
Language: English or French
Phone:
Fax:
Email:

Part D: Alternate sample retention site application

Building where samples are to be retained (Company name & address):
Product name:
Drug Identification Number (DIN):

Privacy notice

The personal information you provide to Health Canada is governed in accordance with the Privacy Act. We only collect the information we need to administer the Food and Drugs Regulations authorized under the Food and Drugs Act.

In limited and specific situations, your personal information may be disclosed without your consent in accordance with subsection 8(2) of the Privacy Act.

For more information: The personal information banks for these collections are described in HC PPU 407 and HC PPU 408 available online at infosource.gc.ca. In addition to protecting your personal information, the Privacy Act gives you the right to request access to and correction of your personal information. For more information about these rights, or about our privacy practices, please contact the Health Canada's Privacy Management Division at 613-948-1219 or hc.privacy-vie.privee.sc@canada.ca.

You also have the right to file a complaint with the Privacy Commissioner of Canada if you think your personal information has been handled improperly.

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: